Grifols (GRFS) to Post Quarterly Earnings on Tuesday

Grifols (NASDAQ:GRFS) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to post earnings of $0.28 per share and revenue of $2.2221 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 12:30 PM ET.

Grifols Trading Up 4.7%

NASDAQ:GRFS opened at $7.61 on Tuesday. Grifols has a 12 month low of $6.96 and a 12 month high of $11.14. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 0.28 and a beta of 0.67. The firm has a fifty day simple moving average of $7.51 and a two-hundred day simple moving average of $8.26.

Grifols Announces Dividend

The business also recently disclosed a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were given a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio is 121.05%.

Analyst Upgrades and Downgrades

GRFS has been the subject of several research reports. Weiss Ratings downgraded Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vinva Investment Management Ltd lifted its stake in shares of Grifols by 10.0% in the fourth quarter. Vinva Investment Management Ltd now owns 28,223 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 2,558 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Grifols by 10.9% during the fourth quarter. Franklin Resources Inc. now owns 21,343 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 2,104 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Grifols during the third quarter worth about $204,000. Aquatic Capital Management LLC bought a new stake in shares of Grifols during the third quarter worth about $236,000. Finally, Orion Porfolio Solutions LLC raised its holdings in shares of Grifols by 83.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 28,743 shares of the biotechnology company’s stock worth $260,000 after acquiring an additional 13,075 shares during the last quarter.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.